Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
about
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Radiolabeled methotrexate as a diagnostic agent of inflammatory target sites: A proof-of-concept study.[Autoimmune reactions to immune checkpoint inhibitors].Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimenImmune-related adverse events of immune checkpoint inhibitors: a brief review
P2860
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
@ast
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
@en
type
label
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
@ast
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
@en
prefLabel
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
@ast
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
@en
P2093
P2860
P1433
P1476
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
@en
P2093
Alan N Baer
Ami A Shah
Clifton O Bingham
Evan J Lipson
Hans J Hammers
Jarushka Naidoo
Jemima Albayda
Julie R Brahmer
Kristen A Marrone
P2860
P304
P356
10.1634/THEONCOLOGIST.2016-0390
P577
2017-06-02T00:00:00Z